Source comparison
GHRP-6 vs Other Growth Hormone Secretagogues: Selectivity and Side Effect Profiles
GHRP-6 belongs to a family of growth hormone secretagogues that includes GHRP-2, Hexarelin, Ipamorelin, and MK-677. While all stimulate GH release, their receptor selectivity and secondary effects differ meaningfully. GHRP-6 vs GHRP-2: Both are first-generatio
This comparison does not assign a generated winner or score.
- GHRP-6 belongs to a family of growth hormone secretagogues that includes GHRP-2, Hexarelin, Ipamorelin, and MK-677. While all stimulate GH release, their receptor selectivity and secondary effects differ meaningfully.
- GHRP-6 vs GHRP-2: Both are first-generation peptides with similar GH-releasing potency, but GHRP-2 produces less appetite stimulation. Approximately 50% lower ghrelin-like hunger signaling compared to GHRP-6. In research models where appetite modulation is undesirable, GHRP-2 is often the preferred alternative.
- GHRP-6 vs Ipamorelin: Ipamorelin is a third-generation peptide engineered for selectivity. It stimulates GH release without activating ghrelin's appetite pathway or triggering cortisol and prolactin elevation (secondary effects observed with GHRP-6 and Hexarelin at higher doses). The trade-off: Ipamorelin's GH pulse is 20–30% lower in magnitude than GHRP-6 at equivalent concentrations.
- GHRP-6 vs Hexarelin: Hexarelin produces the strongest GH pulse of the peptide class but also the highest cortisol co-release. Extended use in animal models showed receptor desensitisation within 4–6 weeks. A phenomenon not observed with GHRP-6 at standard dosing intervals.
- Our experience working with research institutions shows that peptide selection hinges on study design: if appetite modulation is part of the metabolic outcome being studied, GHRP-6 is the logical choice. If GH release needs to be isolated without confounding ghrelin effects, Ipamorelin or GHRP-2 are better suited.